GHK-Cu

GHK-Cu (glycyl-L-histidyl-L-lysine-copper) is a tripeptide-copper complex naturally present in human plasma, saliva, and urine. The peptide GHK binds one copper ion at a 1:1 stoichiometry to form the active complex. It signals tissue repair, modulates over 4,000 human genes, and is the most studied copper-binding peptide in dermatology and regenerative research.

The peptide chain itself is only three amino acids long. The copper coordination is what makes it biologically active. Without copper, GHK has reduced affinity for the cellular machinery that mediates its tissue-repair effects. The complex is small (340 Da), water-soluble, and easily synthesized at high purity.

GHK-Cu carries several names in the literature. Copper tripeptide-1 is the cosmetic ingredient name used in the International Nomenclature of Cosmetic Ingredients (INCI). Iamin and PC1031 were development codes used in early clinical programs. The active substance is identical across these names.

The Clinical Evidence Base

The strongest evidence for GHK-Cu sits in topical dermatology. The clinical file for injectable use is much thinner.

Skin aging. A pilot study in 71 women with photoaged skin reported improved skin density, reduced fine lines, and increased clarity over 12 weeks of topical GHK-Cu cream application (Leyden et al., 2002). A separate study comparing topical GHK-Cu to vitamin C and retinoic acid reported comparable or superior results for collagen synthesis stimulation, with substantially less irritation than retinoic acid produces (Abdulghani et al., 1998).

Diabetic ulcers. A dose-finding open-label trial compared 0.03 percent, 0.3 percent, and 3 percent GHK-Cu injection with saline over 15 days in patients with diabetic foot ulcers. The 3 percent concentration produced the most rapid wound contraction. The trial was small and not blinded, but it remains the cleanest injectable GHK-Cu data in humans.

Hair growth. Topical GHK-Cu has been studied for androgenetic alopecia in small studies showing increased hair density and follicle size. A 2023 review (Pyo et al., Annals of Dermatology, 2023) summarized the mechanisms, including increased dermal blood supply, inhibition of TGF-β1 (which prematurely terminates the hair-growth phase), and stimulation of dermal papilla cells. The clinical-trial dataset for hair indications is limited but mechanistically consistent with the skin results.

Wound healing. A 2015 review in BioMed Research International documented multiple animal-model and small human studies showing accelerated re-epithelialization and improved scar quality. GHK-Cu has been integrated into hospital wound-care products in some countries.

Across all of these, the most replicable finding is collagen synthesis stimulation in topical application. The injectable evidence base, by contrast, is dominated by case series and small open-label trials. No Phase 3 randomized trial of injectable GHK-Cu has been completed for any indication.

GHK-Cu acts as a signaling tripeptide rather than a hormone or receptor agonist. The published mechanism has three main strands.

First, gene expression modulation. A 2010 microarray study in human fibroblasts (Pickart and Margolina, Cosmetics, 2018) reported that GHK-Cu modulates expression of more than 4,000 human genes, with roughly equal numbers up- and down-regulated. The pattern shifts toward a younger expression profile in fibroblasts cultured from older donors. This is the broadest mechanism in the literature and the source of the claim that GHK-Cu "resets" cellular aging.

Second, copper-dependent enzymatic support. Copper is a cofactor for lysyl oxidase, the enzyme that cross-links collagen and elastin in connective tissue. By delivering copper to fibroblasts in a controlled form, GHK-Cu supports the structural protein assembly that produces visible skin tightening and improved tensile strength in healing wounds. Topical application also appears to support superoxide dismutase activity, which contributes to antioxidant defense.

Third, direct angiogenic and chemotactic effects. Animal studies report that GHK-Cu accelerates wound closure by stimulating new blood vessel formation and recruiting macrophages and endothelial cells to injury sites. These effects have been documented in diabetic ulcer trials in animals and small human pilot studies.

The endogenous GHK fragment is liberated from the protein SPARC (secreted protein acidic and rich in cysteine) during tissue injury. This is why plasma GHK rises after wound trauma and falls with age. Exogenous GHK-Cu replicates the signaling without requiring tissue damage to release the fragment.

Regulatory status

GHK-Cu has the most complex compounding status of any peptide on the FDA bulks list.

On September 29, 2023, the FDA placed GHK-Cu on Category 1 of the 503A bulks list for topical routes of administration. Category 1 means the substance has been reviewed and may be used in compounding by 503A pharmacies. The same announcement placed injectable GHK-Cu on Category 2, which prohibits compounding for injection.

On April 15, 2026, the FDA announced that the nominations for injectable GHK-Cu had been withdrawn, removing the substance from Category 2 effective immediately. The agency simultaneously scheduled a PCAC review for the end of February 2027 to determine the regulatory fate of injectable GHK-Cu. During the interim, injectable compounding occupies a legal grey zone.

For topical use, compounded GHK-Cu serums and creams are widely available through 503A pharmacies and from cosmetic brands that use Copper Tripeptide-1 as an over-the-counter ingredient. Concentrations in commercial cosmetics typically range from 0.1 to 2 percent. The FDA does not regulate cosmetics as drugs, so cosmetic GHK-Cu products are subject to ingredient labeling rules but not to efficacy testing.

GHK-Cu does not currently appear on the WADA Prohibited List. This is unusual for a peptide with tissue-repair and angiogenic properties, and it reflects the absence of clinically meaningful systemic effects from topical use. Injectable use in athletes is more ambiguous and could fall under the S0 (Non-Approved Substances) category depending on context.

Dosing protocols and literature-reported ranges are documented in the approved label or trial publications referenced above.

GHK-Cu has a long topical safety record. Allergic contact dermatitis is rare. The most common topical adverse event is mild stinging or transient redness at application sites, which typically resolves within minutes. Copper toxicity from topical application is not a clinical concern at the concentrations used in cosmetic or compounded products.

Injectable GHK-Cu has limited safety data in humans. The diabetic ulcer trial reported no systemic adverse events at the doses tested, but the patient population was small and the duration short. Theoretical concerns include copper accumulation in patients with Wilson disease (a genetic disorder of copper handling), interactions with copper-containing IUDs, and pro-angiogenic effects in patients with established malignancy.

The pro-angiogenic mechanism deserves the same caution that applies to BPC-157 and TB-500. New blood vessel formation supports both wound healing and, theoretically, tumor vascularization. Patients with active or recent cancer should approach systemic peptide therapy with that mechanistic flag in mind.

The most common comparison is between GHK-Cu and matrixyl (palmitoyl pentapeptide-4), another collagen-stimulating cosmetic peptide. The mechanisms differ. Matrixyl signals through a different pathway and does not require copper. Direct comparative trials are limited. Most dermatologists treat the two as complementary rather than competing.

For wound healing and regeneration claims, GHK-Cu sits in a different evidence position than BPC-157 or TB-500. The topical clinical data is the strongest among injectable-research peptides for skin indications. The injectable data is the weakest among the same group, with the smallest published human trials. This is the inverse of the BPC-157 pattern, where the injectable research base is much larger than the topical evidence.

In hair restoration, GHK-Cu is positioned alongside minoxidil and finasteride as part of multi-mechanism protocols. It does not displace either drug. The mechanistic addition is the angiogenic and growth-factor effect on the follicle, complementing the vasodilatory effect of minoxidil and the androgen-blocking effect of finasteride.